During the 8th International Chronic Graft-versus-Host Disease Symposium, the GvHD Hub held a symposium on May 22, 2026, titled “Evolving treatment strategies in SR‑cGvHD: Optimizing patient selection across current and emerging therapies”. Here, we share a presentation by Daniel Wolff, Regensburg, DE, outlining current treatment options for SR-cGvHD.

Wolff reviews available therapeutic options for SR-cGvHD, including key data from pivotal trials of approved and widely adopted therapies. He discusses indications for transitioning to second- and third-line treatments, outlines his approach to managing SR-cGvHD, and highlights remaining unmet treatment needs.

This educational resource is independently supported by Sanofi. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

The GvHD Hub spoke with Corey Cutler, Dana-Farber Cancer Institute, Boston, US. We asked, How do you approach later-line sequencing in cGvHD in your clinical practice? 

Cutler discusses his approach to selecting second-line and subsequent therapies for patients with cGvHD. He explains that, in his practice, treatment selection is guided primarily by FDA approval status and toxicity profiles, while organ involvement plays a more limited, context-dependent role. He highlights patient comorbidities and practical considerations, such as route of administration and dosing frequency, as additional factors that may influence therapy selection.

This educational resource is independently supported by Sanofi. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

Hello, and welcome to our podcast. Today, Robert Zeiser, from the University of Freiburg in Germany, discusses how emerging therapies and combination approaches may reshape treatment sequencing strategies in chronic GvHD.

Intended for healthcare professionals. This educational resource is independently supported by Sanofi. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. 

Hosted on Acast. See acast.com/privacy for more information.

The GvHD Hub spoke with Daniel Wolff, University Hospital Regensburg, Regensburg, DE. We asked, What factors drive your decision to switch from first- to second-line therapy for cGvHD?

During this interview, Wolff discusses factors that guide his decision to escalate from first-line corticosteroids to second-line therapy in cGvHD. When considering a treatment switch, both efficacy and tolerability of steroid therapy should be evaluated, alongside consideration of other patient-related factors such as age, organ involvement, and infectious complications.

This educational resource is independently supported by Sanofi. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

During the 52nd Annual Meeting of the EBMT, the GvHD Hub held a symposium on March 24, 2026, titled “Focusing GvHD care through the eyes of providers and patients: Practical insights on ECP”. Here, we share a presentation by Matea Meden, describing her experience with GvHD.

Matea describes her journey with GvHD, focusing on its profound impact on her physical health, emotional wellbeing, and overall quality of life. She outlines her treatment pathway, which included steroids, ruxolitinib, and extracorporeal photopheresis (ECP). She highlights both the practical and physical challenges of ECP alongside the gradual clinical improvements she experienced. Matea also shares advice for patients with GvHD, encouraging them to trust the ECP treatment process, communicate openly with their healthcare team, and draw strength from their family, peers, and support networks.

This educational resource is independently supported by Therakos. All content was developed by the faculty in collaboration with SES. Funders were allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

During the 52nd Annual Meeting of the EBMT, the GvHD Hub held a symposium on March 24, 2026, titled “Focusing GvHD care through the eyes of providers and patients: Practical insights on ECP”. Here, we share a presentation by Hildegard Greinix, Vienna, AT, describing her approach to treating GvHD with ECP.

Greinix presents two patient case studies illustrating the use of ECP for the management of both acute and chronic GvHD. In both cases, she notes that ECP could be considered a second‑line or later treatment option, either as monotherapy or in combination with other agents, due to its immunomodulatory mechanism of action and favorable safety profile. She also explores key considerations and patient factors that inform treatment selection and initiation.

This educational resource is independently supported by Therakos. All content was developed by the faculty in collaboration with SES. Funders were allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

During the 52nd Annual Meeting of the EBMT, the GvHD Hub held a symposium on March 24, 2026, titled “Focusing GvHD care through the eyes of providers and patients: Practical insights on ECP”. Here, we share a presentation by Michelle Kenyon, London, UK, describing the role of nurses in the care of patients with GvHD.

Kenyon highlights the essential role of nurses in the multidisciplinary management of GvHD, including their involvement in continuous monitoring and assessment of symptoms, administration of treatment regimens and management of complications, alongside their integral role in providing education and support to patients and their families. Kenyon also emphasizes the importance of effective communication, noting that nurses act as key facilitators within the multidisciplinary team to ensure clear information exchange between patients and the wider healthcare team.

This educational resource is independently supported by Therakos. All content was developed by the faculty in collaboration with SES. Funders were allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

The GvHD Hub was pleased to speak with Corey Cutler, Dana-Farber Cancer Institute, Boston, US. We asked, What are the treatment options for chronic GvHD-associated fibrosis?

In this interview, Cutler discusses the development and clinical impact of fibrotic manifestations in chronic graft-versus-host disease (cGvHD), and explores the U.S. Food and Drug Administration (FDA)-approved therapies, including ibrutinib, ruxolitinib, belumosudil, and axatalimab, and the differences in their mechanisms of actions that may influence their use in the treatment of fibrotic disease. He also considers how novel antifibrotic agents might be integrated into the management of fibrotic cGvHD in the future.

This educational resource is independently supported by Sanofi. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.